XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Cumulative Effect Adjustment
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Cumulative Effect Adjustment
Accumulated deficit
Cumulative Effect Adjustment
Total
Balance (in shares) at Dec. 31, 2019 61,935,870              
Balance at the beginning of the period at Dec. 31, 2019 $ 62   $ 1,795,351 $ (10,584)   $ (1,190,499)   $ 594,330
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock related to equity offerings (in shares) 262,205              
Issuance of common stock related to equity offering     13,503         13,503
Exercise of options (in shares) 379,684              
Exercise of options     9,987         9,987
Restricted stock vesting and issuance (in shares) 180,761              
Share-based compensation expense     15,220         15,220
Other           (218)   (218)
Net loss           (112,687)   (112,687)
Comprehensive income       8,599       8,599
Balance (in shares) at Mar. 31, 2020 62,758,520              
Balance at the end of the period at Mar. 31, 2020 $ 62   1,834,061 (1,985)   (1,303,404)   528,734
Balance (in shares) at Dec. 31, 2020 69,718,096              
Balance at the beginning of the period at Dec. 31, 2020 $ 70 $ (175,236) 2,171,746 (60,957) $ 54,796 (1,628,877) $ (120,440) 481,982
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 415,783              
Exercise of options     11,755         11,755
Restricted stock vesting and issuance (in shares) 272,026              
Share-based compensation expense     25,707         25,707
Net loss           (128,642)   (128,642)
Comprehensive income       22,214       22,214
Balance (in shares) at Mar. 31, 2021 70,405,905              
Balance at the end of the period at Mar. 31, 2021 $ 70   $ 2,033,972 $ (38,743)   $ (1,702,723)   $ 292,576